Author: Zeena Haress

When it comes to photobiomodulation (PBM), itʼs definitely tempting to compare
devices by the simplest visible metric, how much light they produce. Larger panels
appear more powerful, and power can seem like a natural shorthand for effectiveness.
But this comparison becomes misleading when two devices are designed for
fundamentally different biological purposes.

A broad red or near-infrared light panel and a targeted brain-focused device are not
simply larger and smaller versions of the same idea, they represent different treatment
philosophies: One is built around wide-area exposure, while the other is built around
anatomically directed neuromodulation, as well as the potential to engage not only the
brain itself but also the wider physiological systems that shape brain health.

Panels Are Broad-Field Tools

Large-format light panels are best understood as broad-field photobiomodulation
systems. Their defining feature is coverage: they illuminate a relatively large surface
area of the body at once. This makes them well suited to applications where the
therapeutic aim is general tissue exposure, such as skin, muscle, joints, or other
superficial and regional body tissues.

But donʼt get me wrong, this does not make panels unsophisticated.
Photobiomodulation has a substantial evidence base showing that red and near-infrared
light can influence mitochondrial activity, oxidative balance, inflammatory signalling, and
tissue recovery. Across the wider PBM literature, these mechanisms are relevant to
wound healing, pain modulation, inflammation, and cellular energy metabolism.
But a broad illumination strategy is not the same as a brain-optimised delivery strategy.
When the intended target is neural tissue, the scientific question changes. It is no
longer only, “How much light is emitted?” It becomes:

• Which anatomical structures of the brain are being targeted?
• How effectively can the wavelength and delivery geometry interact with tissues of
  the head?

These questions define transcranial and brain-directed photobiomodulation research.

Brain Photobiomodulation As a Distinct Scientific Category

Brain photobiomodulation, or transcranial PBM, uses red or near-infrared light delivered
to the head to influence underlying neural tissue. Unlike general whole-body light
exposure, it is defined by factors such as placement, wavelength, optical penetration,
cerebral blood flow, and neural function.

Experimental and early clinical research has linked transcranial PBM to effects on brain
energy metabolism, mitochondrial cytochrome c oxidase activity, oxidative stress,
neuroinflammatory pathways, cerebral blood flow, and selected cognitive or
neurological outcomes. Although the evidence is still evolving, brain PBM clearly has its
own anatomical and mechanistic rationale. It is not simply a lower-powered version of
skin or muscle PBM. A large panel may deliver substantial light broadly, but it is not specifically designed to address the challenge of reaching and modulating neural
targets through the scalp and skull.

The Brain Does Not Operate in Isolation

Brain health is shaped by continuous communication with the rest of the body,
especially through the gut‒brain axis: a bidirectional network linking the gut,
microbiome, immune and endocrine systems, and the central nervous system. This
communication occurs through vagal signalling, inflammatory mediators, microbial
metabolites, neuroendocrine pathways, and circulating gut-derived molecules. The
vagus nerve is particularly important, providing a direct route through which the gut
and brain exchange information. Because brain function is influenced by systemic
inflammation, metabolic state, gut signalling, and microbiome activity, brain support
cannot always be understood through a purely local “light on the head” model alone.

Why the Gut Matters in a Brain-Focused PBM Strategy

Combining brain- and gut-directed PBM reflects a systems-level approach to
neuromodulation. Emerging preclinical and review evidence suggests that abdominal
PBM may influence gut microbial composition, intestinal inflammation, and systemic
immune signalling; all of which can affect brain function through the gut‒brain axis.
This is particularly relevant in neurodegenerative research (Alzheimerʼs, Parkinsonʼs,
etc), where microbiome disruption, peripheral inflammation, and altered gut‒brain
communication are increasingly linked to neurological dysfunction. For this reason,
some PBM researchers have proposed a dual-site strategy: targeting the brain directly
while also addressing peripheral gut-derived signals that may shape neural health.
The evidence remains early and should not be overstated. However, it supports a
scientifically credible rationale: gut-brain axis modulation is a meaningful PBM target
when the aim is to engage both central and systemic contributors to brain function.

A Systems-Level Device Is Not Competing on the Same Axis as a Panel

This is where the comparison between panels and CeraThrive becomes clearer.
A panel asks: How broadly can light be delivered across the body?
Whereas a targeted brain‒gut system asks:
How can light be directed toward biologically strategic sites that participate in neural
regulation and systemic communication?
These are not the same design goals.
Panels can be valuable tools for wide-area photobiomodulation. But they are not
inherently designed around brain-specific anatomical delivery, head-directed
neuromodulation, gut‒brain axis relevance, paired central and peripheral targeting, or a
systems-level model of neurological support.

Brain-targeted PBM devices are built from a different premise: that placement,
biological pathway, and tissue specificity matter as much as raw output. The addition of
gut-directed treatment pushes this concept further, aligning with evidence that the brain is influenced by peripheral physiological systems rather than operating as an
isolated organ.

Why This Matters for CeraThrive

CeraThrive should not be positioned as a smaller alternative to a high-powered panel. It
is better understood as a different class of photobiomodulation system: one designed
around targeted brain support and brain-gut integration. That distinction is important because it changes the standard of comparison. The most relevant question is not whether a targeted device emits more light than a panel. The more meaningful question is whether the device is designed around the specific biology of the brain, and the possibility that central and peripheral photobiomodulation may be complementary.

That is a more sophisticated frame than power alone.

Different Tools, Different Biological Intentions

Broad photobiomodulation panels and targeted brain‒gut devices can both belong
within the wider PBM landscape. But they should not be treated as interchangeable.
Panels are built for coverage.
Brain-directed systems are built for specificity.
Brain‒gut systems go further, aiming for integration.
As PBM science develops, the field is moving beyond the simplistic assumption that
“more light” automatically means “better therapy.” In brain-focused applications
especially, the science points toward a more nuanced principle: effective design
depends on matching the delivery strategy to the biology being addressed.
For CeraThrive, that is the central message. It is not trying to be a panel. It is pursuing a
more targeted, systems-aware approach to photobiomodulation; one grounded in the
distinct biology of the brain and its intimate dialogue with the gut.

References

1. Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018). Vagus nerve as modulator of the brain‒gut axis in psychiatric and inflammatory disorders. Frontiers in Psychiatry, 9, 44.
2. Carabotti, M., Scirocco, A., Maselli, M. A., & Severi, C. (2015). The gut‒brain axis:
   Interactions between enteric microbiota, central and enteric nervous systems.
   Annals of Gastroenterology, 28(2), 203‒209.
3. Cryan, J. F., OʼRiordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S.,
   Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., Guzzetta, K. E., Jaggar, M., Long-Smith, C. M., Lyte, J. M., Martin, J. A., Molinero-Perez, A.,
   Moloney, G., Morelli, E., Morillas, E., ... Dinan, T. G. (2019). The microbiota‒gut‒brain axis. Physiological Reviews, 99(4), 1877‒2013.
4. Fernandes, F., et al. (2024). Devices used for photobiomodulation of the brain: A
   systematic review. Journal of Photochemistry and Photobiology B: Biology.
5. Guimarães, G. N. F., et al. (2025). Abdominal photobiomodulation and the gut‒brain axis. Biomedicines.
6. Hamblin, M. R. (2016). Shining light on the head: Photobiomodulation for brain disorders. BBA Clinical, 6, 113‒124.
7. Hennessy, M., & Hamblin, M. R. (2016). Photobiomodulation and the brain: A new
   paradigm. Journal of Optics, 19(1), 013003.
8. Jahani-Sherafat, S., et al. (2023). The effectiveness of photobiomodulation therapy in regulating gut microbiota and inflammatory pathways: A review. Lasers in Medical Science.
9. Liebert, A., Bicknell, B., Johnstone, D. M., Gordon, L. C., Kiat, H., & Hamblin, M. R.
   (2019). Can light, including photobiomodulation, alter the microbiome?
   Photobiomodulation, Photomedicine, and Laser Surgery, 37(11), 681‒693.
10. Naeser, M. A., et al. (2016). Transcranial, red/near-infrared light-emitting diode
    therapy to improve cognition in chronic traumatic brain injury. Photomedicine and
    Laser Surgery, 34(12), 610‒626.
11. Salehpour, F., Ahmadian, N., Rasta, S. H., Farhoudi, M., Karimi, P., & Sadigh-Eteghad, S. (2018). Brain photobiomodulation therapy: A narrative review. Molecular Neurobiology, 55(8), 6601‒6636.
12. Salehpour, F., Gholipour-Khalili, S., Farajdokht, F., Kamari, F., Walski, T., Hamblin, M. R., & DiDuro, J. O. (2019). Penetration profiles of visible and near-infrared lasers and light-emitting diode light through the head tissues in animal and human species: A review of literature. Photobiomodulation, Photomedicine, and Laser Surgery, 37(10), 581‒595.
13. Wang, X., et al. (2017). Up-regulation of cerebral cytochrome-c-oxidase and
    hemodynamics by transcranial infrared laser stimulation: A broadband near-infrared spectroscopy study. Journal of Cerebral Blood Flow & Metabolism, 37(12), 3789‒3802.
14. Blivet, G., et al. (2024). A novel therapeutic approach to Alzheimerʼs disease by
    photobiomodulation of the brain-gut axis. Current Alzheimer Research.